Sufi Mary Thomas

List of Publications by Year
in descending order

94 papers	5,671 citations	57719 44 h-index	76872 74 g-index
99 all docs	99 docs citations	99 times ranked	8271 citing authors

#	Article	IF	Citations
1	Mitogen‑activated protein kinase‑activated protein kinase‑2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancer. Molecular Carcinogenesis, 2022, 61, 173-199.	1.3	9
2	Vasopressin Receptor Type-2 Mediated Signaling in Renal Cell Carcinoma Stimulates Stromal Fibroblast Activation. International Journal of Molecular Sciences, 2022, 23, 7601.	1.8	1
3	Evaluating the role of RNA binding protein CELF2 in modulating immune cells in colitis. FASEB Journal, 2021, 35, .	0.2	0
4	DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene, 2021, 40, 5013-5025.	2.6	18
5	Abstract 3170: Targeting tumor-associated astrocyte dependence in glioblastoma treatment. , 2021, , .		1
6	Mechanical Properties in the Glioma Microenvironment: Emerging Insights and Theranostic Opportunities. Frontiers in Oncology, 2021, 11, 805628.	1.3	12
7	Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene, 2020, 39, 1231-1245.	2.6	31
8	Occupational exposure of oropharyngeal human papillomavirus amongst otolaryngologists. Laryngoscope, 2020, 130, 2366-2371.	1.1	10
9	Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology, 2020, 158, 1433-1449.e27.	0.6	23
10	Multicellular contractility contributes to the emergence of mesothelioma nodules. Scientific Reports, 2020, 10, 20114.	1.6	2
11	Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway. Scientific Reports, 2020, 10, 1290.	1.6	44
12	RNA Binding Protein RBM3 Modulates Novel LncRNAs to Increase Tumor Progression in Colon Cancer Cells. FASEB Journal, 2020, 34, 1-1.	0.2	0
13	Understanding the Metabolic Cross Talk Between Cancer Cells and Cancer-Associated Fibroblasts. , 2020, , 39-53.		0
14	The role of the innate and adaptive immune response in HPV‑associated oropharyngeal squamous cell carcinoma. Laryngoscope Investigative Otolaryngology, 2019, 4, 508-512.	0.6	10
15	The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice. Gastroenterology, 2019, 157, 1646-1659.e11.	0.6	50
16	Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response. Cancer Research, 2019, 79, 1681-1695.	0.4	40
17	Pleotropic role of RNA binding protein CELF2 in autophagy induction. Molecular Carcinogenesis, 2019, 58, 1400-1409.	1.3	26
18	Autophagy-dependent secretion: mechanism, factors secreted, and disease implications. Autophagy, 2019, 15, 1682-1693.	4.3	138

#	ARTICLE	IF	CITATIONS
19	A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies.. Journal of Clinical Oncology, 2019, 37, TPS3165-TPS3165.	0.8	3
20	Targeting transcription factor TCF4 by Î³-Mangostin, a natural xanthone. Oncotarget, 2019, 10, 5576-5591.	0.8	14
21	Differential Gene Expression and Pathway Analysis in Juvenile Nasopharyngeal Angiofibroma Using RNA Sequencing. Otolaryngology - Head and Neck Surgery, 2018, 159, 572-575.	1.1	5
22	A Review of Promising Natural Chemopreventive Agents for Head and Neck Cancer. Cancer Prevention Research, 2018, 11, 441-450.	0.7	32
23	Development and Characterization of an In Vitro Model for Radiation-Induced Fibrosis. Radiation Research, 2018, 189, 326.	0.7	11
24	Phase 1 study of EGFRâ€antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. Cancer, 2018, 124, 3881-3889.	2.0	8
25	Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Research, 2018, 78, 3769-3782.	0.4	96
26	Quantitative clinical outcomes of therapy for head and neck lymphedema. Advances in Radiation Oncology, 2018, 3, 366-371.	0.6	20
27	Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Frontiers in Oncology, 2018, 8, 203.	1.3	170
28	Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds. Scientific Reports, 2018, 8, 12163.	1.6	24
29	Targeting the Prolactin Receptor Signaling Using an Antipsychotic Drug to Suppress Pancreatic Cancer. FASEB Journal, 2018, 32, 610.3.	0.2	0
30	Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target. Cancer Research, 2017, 77, 6679-6691.	0.4	139
31	Inhibition of fibroblast growth factor receptor with AZD4547 mitigates juvenile nasopharyngeal angiofibroma. International Forum of Allergy and Rhinology, 2017, 7, 973-979.	1.5	7
32	Stromal contributions to the carcinogenic process. Molecular Carcinogenesis, 2017, 56, 1199-1213.	1.3	37
33	Activated HGF-c-Met Axis in Head and Neck Cancer. Cancers, 2017, 9, 169.	1.7	51
34	Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells. BMC Cancer, 2016, 16, 487.	1.1	54
35	Proteomic Characterization of Head and Neck Cancer Patientâ€"Derived Xenografts. Molecular Cancer Research, 2016, 14, 278-286.	1.5	48
36	The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget, 2016, 7, 27185-27198.	0.8	37

#	Article	IF	Citations
37	Abstract 1030: Targeting tumor-stroma metabolic symbiosis for head and neck cancer therapy. , 2016, , .		0
38	Tumor matrix protein collagen XIα1 in cancer. Cancer Letters, 2015, 357, 448-453.	3.2	73
39	Radiation-induced fibrosis: mechanisms and implications for therapy. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1985-1994.	1.2	391
40	Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti–Hepatocyte Growth Factor Antibody Ficlatuzumab. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 1133.	1.2	43
41	Perineural growth in head and neck squamous cell carcinoma: A review. Oral Oncology, 2015, 51, 16-23.	0.8	98
42	Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor‐associated fibroblasts in preclinical models. Head and Neck, 2014, 36, 385-392.	0.9	88
43	Issues in Moving Gene Therapy Approaches to Early Clinical Trials. , 2014, , 493-501.		0
44	Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer. Clinical Cancer Research, 2014, 20, 3289-3298.	3.2	48
45	Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models. ACS Chemical Biology, 2013, 8, 345-352.	1.6	41
46	Expression of EGFR, VEGF, and NOTCH1 Suggest Differences in Tumor Angiogenesis in HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma. Head and Neck Pathology, 2013, 7, 344-355.	1.3	39
47	Molecular communication between tumor-associated fibroblasts and head and neck squamous cell carcinoma. Oral Oncology, 2013, 49, 381-386.	0.8	45
48	Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies. Clinical Cancer Research, 2013, 19, 1244-1256.	3.2	56
49	c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met. Clinical Cancer Research, 2013, 19, 380-392.	3.2	90
50	Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion. British Journal of Cancer, 2013, 109, 3049-3056.	2.9	47
51	Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 16-31.	1.0	6
52	First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy. Cancer Discovery, 2012, 2, 694-705.	7.7	260
53	Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer. Clinical Cancer Research, 2012, 18, 4986-4996.	3.2	135
54	Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy. Clinical Cancer Research, 2012, 18, 5639-5649.	3.2	72

#	Article	IF	Citations
55	The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy, 2012, 8, 1873-1874.	4.3	61
56	Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer. Molecular Cancer Therapeutics, 2012, 11, 1236-1246.	1.9	21
57	Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: A pilot randomized trial in head and neck cancer. Oral Oncology, 2012, 48, 1136-1145.	0.8	11
58	Targeting TORC1/2 Enhances Sensitivity to EGFR Inhibitors in Head and Neck Cancer Preclinical Models. Neoplasia, 2012, 14, 1005-1014.	2.3	40
59	Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncology, 2011, 47, 961-966.	0.8	47
60	Inhibition of EGFR-STAT3 Signaling with Erlotinib Prevents Carcinogenesis in a Chemically-Induced Mouse Model of Oral Squamous Cell Carcinoma. Cancer Prevention Research, 2011, 4, 230-237.	0.7	55
61	Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab. Clinical Cancer Research, 2011, 17, 4996-5004.	3.2	26
62	Targeting mesenchymal exaptation to mitigate tumor growth. Cell Cycle, 2011, 10, 2626-2627.	1.3	2
63	Abstract 561: Tumor-associated fibroblast-induced head and neck squamous cell carcinoma invasion can be abrogated by c-Src and c-Met inhibition. , 2011, , .		0
64	Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene, 2010, 29, 5135-5145.	2.6	94
65	Correction: HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer. Clinical Cancer Research, 2010, 16, 4298-4300.	3.2	0
66	Epidermal Growth Factor Receptor Expression and Gene Copy Number in the Risk of Oral Cancer. Cancer Prevention Research, 2010, 3, 800-809.	0.7	108
67	Honokiol Inhibits Epidermal Growth Factor Receptor Signaling and Enhances the Antitumor Effects of Epidermal Growth Factor Receptor Inhibitors. Clinical Cancer Research, 2010, 16, 2571-2579.	3.2	95
68	The Current State of Head and Neck Cancer Gene Therapy. Human Gene Therapy, 2009, 20, 1565-1575.	1.4	40
69	Human rhomboid familyâ€1 gene<i>RHBDF1</i>participates in GPCRâ€mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB Journal, 2009, 23, 425-432.	0.2	72
70	Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis, 2009, 30, 1848-1856.	1.3	96
71	Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. Journal of Clinical Oncology, 2009, 27, 1235-1242.	0.8	63
72	HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer. Clinical Cancer Research, 2009, 15, 3740-3750.	3.2	196

#	Article	IF	Citations
73	Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemotherapy and Pharmacology, 2009, 63, 983-995.	1.1	47
74	PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene, 2009, 28, 2348-2357.	2.6	62
75	Synthesis of Conformationally Preorganized and Cell-Permeable Guanidine-Based Î³-Peptide Nucleic Acids (Î³GPNAs). Journal of Organic Chemistry, 2009, 74, 1509-1516.	1.7	98
76	Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia, 2008, 22, 1624-1627.	3.3	18
77	Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2008, 14, 4284-4291.	3.2	95
78	Combined Inhibition of PLCÎ³-1 and c-Src Abrogates Epidermal Growth Factor Receptorâ€"Mediated Head and Neck Squamous Cell Carcinoma Invasion. Clinical Cancer Research, 2008, 14, 4336-4344.	3.2	38
79	Antitumor Mechanisms of Systemically Administered Epidermal Growth Factor Receptor Antisense Oligonucleotides in Combination with Docetaxel in Squamous Cell Carcinoma of the Head and Neck. Molecular Pharmacology, 2008, 73, 627-638.	1.0	12
80	Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Molecular Cancer Therapeutics, 2007, 6, 1414-1424.	1.9	73
81	Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer. Clinical Cancer Research, 2007, 13, 1892-1902.	3.2	130
82	Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting. Clinical Cancer Research, 2006, 12, 5064-5073.	3.2	440
83	Motility in Head and Neck Carcinoma. , 2006, , 245-264.		1
84	Phosphorylation of TNF-Â converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6901-6906.	3.3	130
85	Cross-talk between G Proteinâ€"Coupled Receptor and Epidermal Growth Factor Receptor Signaling Pathways Contributes to Growth and Invasion of Head and Neck Squamous Cell Carcinoma. Cancer Research, 2006, 66, 11831-11839.	0.4	131
86	Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene, 2005, 24, 5897-5904.	2.6	90
87	Gastrin-Releasing Peptide Receptor Mediates Activation of the Epidermal Growth Factor Receptor in Lung Cancer Cells. Neoplasia, 2005, 7, 426-431.	2.3	51
88	Src Family Kinases Mediate Epidermal Growth Factor Receptor Ligand Cleavage, Proliferation, and Invasion of Head and Neck Cancer Cells. Cancer Research, 2004, 64, 6166-6173.	0.4	149
89	Abrogation of Head and Neck Squamous Cell Carcinoma Growth by Epidermal Growth Factor Receptor Ligand Fused to Pseudomonas Exotoxin Transforming Growth Factor Î±-PE38. Clinical Cancer Research, 2004, 10, 7079-7087.	3.2	16
90	Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treatment Reviews, 2004, 30, 255-268.	3.4	156

#	Article	IF	Citations
91	Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy. Cancer Gene Therapy, 2003, 10, 518-528.	2.2	15
92	Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene, 2003, 22, 6183-6193.	2.6	78
93	Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Research, 2003, 63, 5629-35.	0.4	83
94	Establishment of a human squamous cell carcinoma cell line of the upper aero-digestive tract. Cancer Letters, 1997, 118, 115-121.	3.2	27